Novartis has announced that its 744-patient randomized, double-blind, 26-week LANTERN study has demonstrated that the once-daily Ultibro Breezhaler indacaterol/glycopyrronium bromide DPI reduced exacerbations in moderate-to-severe COPD patients by 31% compared to twice-daily Advair Diskus (Seretide Accuhaler) salmeterol/fluticasone DPI.
The new data were announced at the European Respiratory Society (ERS) International Congress. Earlier this year, Novartis announced that the LANTERN study showed superior efficacy for Ultibro, including improved lung function compared to Advair.
Novartis Global Head of Development Vasant Narasimhan said, “These new results from LANTERN provide further evidence of the potential of Ultibro Breezhaler to deliver better exacerbation reduction and improvements in lung function, compared to the current standard of care.”
Read the Novartis press release.
